ArticleScience advances2025
An enzymatic cleavage-triggered minimally invasive nanosensor for urine-based detection of early atherosclerosis.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Nanomaterial-Enabled Fiber-Optic SPR Biosensor for Continuous and Noninvasive Body Fluid Monitoring:Progress and Prospects.Nanomaterials (Basel, Switzerland) · 2026Review
- Advances in quantum dot-based fluorescent biosensors for enzyme detection: mechanistic insights and applications in disease.Mikrochimica acta · 2026Review
- Urinary detection of therapy-induced senescence and fibrosis using an injectable albumin-based nanoprobe.Nature aging · 2026Article
- A hierarchical theranostic nanoagent for multimodal imaging and targeted foam cell intervention in atherosclerosis.Nature communications · 2026Article
- PSA-Responsive Aptamer-Based Switchable Aggregates of Ultrasmall Gold Nanoparticles.Sensors (Basel, Switzerland) · 2025Article
- Thiol-polarity dual cascade-triggered two-photon imaging of protein unfolding for early atherosclerosis diagnosis.Science advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Timely detection of early atherosclerosis (AS) is crucial for improving cardiovascular outcomes, creating a growing demand for diagnostic tools that are simple, sensitive, and cost-effective. Here, we introduce a synthetic nanosensor for early AS detection that leverages the fluorescence and renal clearance properties of carbon quantum dots (CQDs). This nanosensor, designed to respond to the proteolytic activity of AS-associated dysregulated enzymes, entails CQDs as signal reporters to convert AS-associated proteolytic activity to fluorometric readings enabling a sensitive and cost-effective urine-based assay for early AS detection. Our findings demonstrated that the nanosensor provided distinct signals in atherosclerotic versus healthy mice at early AS stages, indicating its diagnostic potential. Moreover, toxicity tests showed no notable adverse effects, supporting its safety for diagnostic applications. This minimally invasive diagnostic approach could facilitate personalized therapy design and continuous efficacy assessment. It is expected that such a modular nanosensor platform can be integrated with simple urine tests to offer cost-effective detection of various diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.